DNMT1 and neoplasm: The two FDA-approved DNMT inhibitors, 5-azacytidine and decitabine (5-aza-dC), and four approved HDAC inhibitors, vorinostat, romidepsin, panobinostat, and belinostat, have mainly been used in clinical trials and have demonstrated anti-tumor potential towards various cancers [10].